SpaBlack Logo

Click to Call

a

Spa Black Laser Cellulite and Lipo Med Spa

LOCATION

7272 Wurzbach Rd. Suite 801 & 804
San Antonio, TX 78240

PHONE

(210) 750-6441

Video cover for Jeuveau.

The fresh approach to an age-old problem.

Modern made using Hi-Pure technology, Jeauveu temporarily smooths the appearance of moderate to severe frown lines.

 

Get your free consultation or check out the video to learn more!

Click to Call or Dial (210) 750-6441
Jeuveau® is a prescription medicine that is injected into muscles and used in adults for a short period of time (temporary) to improve the look of moderate to severe frown lines between the eyebrows (glabellar lines).
jeuveau logo

Offer – $99 for 20 units*

*new patients only

Please select one:

Meghan

Meghan

Ann

Ann

Amy

Amy

Sharon

Sharon

Portrait of Meghan, jeveau patient

*JEUVEAU® patient at maximum frown. Individual results may vary

Portrait of Meghan, jeveau patient

In a study conducted in Europe and Canada, 54% of patients had a >1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint). In US studies, 46% and 56% had a >1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint). Results based on a 1-grade improvement may not be considered clinically meaningful.

*JEUVEAU® patient at maximum frown. Individual results may vary

Portrait of Meghan, jeveau patient
In two US studies, the overall efficacy of Jeuveau® was evaluated using a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30 at 68% and 70%, respectively.

*JEUVEAU® patient at maximum frown. Individual results may vary

Portrait of Meghan, jeveau patient
In a study conducted in Europe and Canada, 38% of patients had a >1-grade improvement in frown lines at 5 months based on physician assessment compared to 8% for placebo (secondary endpoint). In US studies, almost 5% of patients had a >2-grade improvement in frown lines at 5 months based on both patient and physician assessments compared to 0% for placebo (secondary endpoint). Results based on a 1-grade improvement may not be considered clinically meaningful.

*JEUVEAU® patient at maximum frown. Individual results may vary

Portrait of Ann, jeveau patient

*JEUVEAU® patient at maximum frown. Individual results may vary

Portrait of Ann, jeveau patient
In a study conducted in Europe and Canada, 54% of patients had a >1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint). In US studies, 46% and 56% had a >1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint). Results based on a 1-grade improvement may not be considered clinically meaningful.

*JEUVEAU® patient at maximum frown. Individual results may vary

Portrait of Ann, jeveau patient
In two US studies, the overall efficacy of Jeuveau® was evaluated using a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30 at 68% and 70%, respectively.

*JEUVEAU® patient at maximum frown. Individual results may vary

Portrait of Ann, jeveau patient
In a study conducted in Europe and Canada, 38% of patients had a >1-grade improvement in frown lines at 5 months based on physician assessment compared to 8% for placebo (secondary endpoint). In US studies, almost 5% of patients had a >2-grade improvement in frown lines at 5 months based on both patient and physician assessments compared to 0% for placebo (secondary endpoint). Results based on a 1-grade improvement may not be considered clinically meaningful.

*JEUVEAU® patient at maximum frown. Individual results may vary

Portrait of Jeveau patient

*JEUVEAU® patient at maximum frown. Individual results may vary

Portrait of Jeveau patient
In a study conducted in Europe and Canada, 54% of patients had a >1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint). In US studies, 46% and 56% had a >1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint). Results based on a 1-grade improvement may not be considered clinically meaningful.

*JEUVEAU® patient at maximum frown. Individual results may vary

Portrait of Jeveau patient
In two US studies, the overall efficacy of Jeuveau® was evaluated using a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30 at 68% and 70%, respectively.

*JEUVEAU® patient at maximum frown. Individual results may vary

Portrait of Jeveau patient
In a study conducted in Europe and Canada, 38% of patients had a >1-grade improvement in frown lines at 5 months based on physician assessment compared to 8% for placebo (secondary endpoint). In US studies, almost 5% of patients had a >2-grade improvement in frown lines at 5 months based on both patient and physician assessments compared to 0% for placebo (secondary endpoint). Results based on a 1-grade improvement may not be considered clinically meaningful.

*JEUVEAU® patient at maximum frown. Individual results may vary

Portrait of Sharon, Jeveau patient.

*JEUVEAU® patient at maximum frown. Individual results may vary

Portrait of Sharon, Jeveau patient.
In a study conducted in Europe and Canada, 54% of patients had a >1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint). In US studies, 46% and 56% had a >1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint). Results based on a 1-grade improvement may not be considered clinically meaningful.

*JEUVEAU® patient at maximum frown. Individual results may vary

Portrait of Sharon, Jeveau patient.
In two US studies, the overall efficacy of Jeuveau® was evaluated using a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30 at 68% and 70%, respectively.

*JEUVEAU® patient at maximum frown. Individual results may vary

Portrait of Sharon, Jeveau patient.
In a study conducted in Europe and Canada, 38% of patients had a >1-grade improvement in frown lines at 5 months based on physician assessment compared to 8% for placebo (secondary endpoint). In US studies, almost 5% of patients had a >2-grade improvement in frown lines at 5 months based on both patient and physician assessments compared to 0% for placebo (secondary endpoint). Results based on a 1-grade improvement may not be considered clinically meaningful.

*JEUVEAU® patient at maximum frown. Individual results may vary

Real Results

In a survey of >9,000 people treated with Jeuveau® *

%

were satisfied with their overall Jeuveau® treatment

%

believe results with Jeuveau® are natural-looking

*J.E.T. Survey data collected 30 days after treatment, December 2019 (n=9,151); Somewhat to strongly agreed on a 5-point rating scale. Slightly to extremely satisfied on a 5-point rating scale

Meet Thomas T. Jeneby, M.D.

Board Certified Plastic Surgeon

Award Winning Medspas. Award Winning Plastic Surgeon. Injectors with Combined 30 year Experience Lasers and Minimally Invasive devices to Turn Back the Clock

2 Locations to Serve You

Pause your frown lines & book a free consultation today!

"*" indicates required fields

Hidden
Consent*
This field is for validation purposes and should be left unchanged.

Spa Black Laser Cellulite and Lipo Med Spa

A bottle of Jeuveau with glitter streaming from the top.

IMPORTANT SAFETY INFORMATION FOR JEUVEAU® (prabotulinumtoxinA-xvfs)

JEUVEAU® may cause serious side effects that can be life threatening. Get medical help right away if you have any of these problems any time (hours to weeks) after injection of JEUVEAU®: • Problems swallowing, speaking, or breathing, due to weakening of associated muscles, can be severe and result in loss of life. You are at the highest risk if these problems are pre-existing before injection. Swallowing problems may last for several months. • Spread of toxin effects. The effect of botulinum toxin may affect areas away from the injection site and cause serious symptoms including: loss of strength and all-over muscle weakness, double vision, blurred vision and drooping eyelids, hoarseness or change or loss of voice, trouble saying words clearly, loss of bladder control, trouble breathing, trouble swallowing. Do not use JEUVEAU® if you: are allergic to any of the ingredients in JEUVEAU® (see Medication Guide for ingredients); had an allergic reaction to any other botulinum toxin product such as rimabotulinumtoxinB (MYOBLOC®), onabotulinumtoxinA (BOTOX®/BOTOX® Cosmetic), abobotulinumtoxinA (DYSPORT®), or incobotulinumtoxinA (XEOMIN®); have a skin infection at the planned injection site; or are a child. JEUVEAU® dosing units are not the same as, or comparable to, any other botulinum. Tell your healthcare provider about all your muscle or nerve conditions, such as ALS or Lou Gehrig’s disease, Myasthenia gravis, or Lambert-Eaton syndrome, as you may be at increased risk of serious side effects including difficulty swallowing and difficulty breathing from typical doses of JEUVEAU®. Tell your healthcare provider about all your medical conditions, including: any side effects from botulinum toxin products, including dry eye; breathing, swallowing, bleeding, or heart problems; plans to have surgery; weakness of forehead muscles; drooping eyelids; have had surgery on your face; are pregnant or breastfeeding or plan to become pregnant or breastfeed (it is not known if JEUVEAU® can harm your unborn baby or passes into breast milk). Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Using JEUVEAU® with certain other medicines may cause serious side effects. Do not start any new medicines until you have told your healthcare provider that you have received JEUVEAU® in the past. Especially tell your healthcare provider if you: have received any other botulinum toxin product in the past and the last 4 months, and exactly which product you received (such as BOTOX, BOTOX Cosmetic, MYOBLOC, DYSPORT, or XEOMIN). JEUVEAU® may cause loss of strength or general muscle weakness, vision problems, or dizziness within hours to weeks of treatment with JEUVEAU®. If this happens, do not drive a car, operate machinery, or do other dangerous activities. JEUVEAU® can cause other serious side effects including: allergic reactions such as itching, rash, red itchy welts, wheezing, trouble breathing, asthma symptoms, or dizziness or feeling faint. Tell your healthcare provider or get emergency medical help right away if you develop wheezing or trouble breathing, or if you feel dizzy or faint. Heart problems. Irregular heartbeat and heart attack that have caused death, have happened in some people who received botulinum toxin products. Eye problems such as dry eye, reduced blinking, and corneal problems. Tell your healthcare provider if you develop eye pain or irritation, sensitivity to light, or changes in your vision. The most common side effects include: headache; eyelid drooping, upper respiratory tract infection, and increased white blood cell count. APPROVED USE JEUVEAU® is a prescription medicine that is injected into muscles and used in adults for a short period of time (temporary) to improve the look of moderate to severe frown lines between the eyebrows (glabellar lines). The risk information provided here is not complete. For more information about JEUVEAU®, see the full Prescribing Information including BOXED WARNING, and Medication Guide, or talk to your healthcare provider. To report side effects associated with use of JEUVEAU®, please call 1-877-EVOLUS1/1-877-386-5871. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. Exclusively licensed and manufactured for: Evolus, Inc., 520 Newport Center Drive, Suite 1200, Newport Beach, CA 92660 ©2020 Evolus, Inc. All rights reserved. All trademarks are the property of their respective owners.